TY - JOUR T1 - Pre exposure hydroxychloroquine prophylaxis for covid-19 in healthcare workers: a retrospective cohort JF - medRxiv DO - 10.1101/2020.06.09.20116806 SP - 2020.06.09.20116806 AU - Raja Bhattacharya AU - Sampurna Chowdhury AU - Rishav Mukherjee AU - Anita Nandi AU - Manish Kulshrestha AU - Rohini Ghosh AU - Souvik Saha Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/01/2020.06.09.20116806.abstract N2 - BACKGROUND OF STUDY While several trials are ongoing for treatment of COVID-19, scientific research on chemoprophylaxis is still lacking even though it has potential to flatten the curve allowing us time to complete research on vaccines.OBJECTIVES OF THE STUDY To explore the potential of HCQ as a pre-exposure prophylaxis for COVID 19 in health care workers in a tertiary care hospital.MATERIALS & METHODS We have conducted a retrospective cohort study among 106 Health Care Workers (HCW) exposed to COVID-19 patients, at a tertiary care hospital in India where there was an abrupt cluster outbreak within on duty personnel. HCWs who had voluntarily taken hydroxychloroquine (HCQ) prior to exposure were considered one cohort while those who had not were considered to be the Control group. All participants with a verifiable high risk contact history were tested for COVID-19 by RT-PCR.RESULTS The two cohorts were comparable in terms of age, gender, co-morbidities and exposure. The primary outcome was incidence rates of RT-PCR positive COVID-19 infection amongst HCQ users and Controls. In this retrospective cohort study, 106 healthcare workers were examined of whom 54 were HCQ users and rest were not. The comparative analysis of incidence of infection between the two groups demonstrated that voluntary HCQ usage was associated with lesser likelihood of developing SARS-CoV-2 infection (4 out of 54 HCW), compared to those who were not on it (20 out of 52 HCW), χ2 =14.59, p<0.001. None of the HCQ users noted any serious adverse effects.CONCLUSIONS This study demonstrated that voluntary HCQ consumption as pre-exposure prophylaxis by HCWs is associated with a statistically significant reduction in risk of SARS-CoV-2. These promising findings therefore highlight the need to examine this association in greater detail among a larger sample using Randomised Controlled Trials (RCT).Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee approved this observational study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is available within manuscript file.HCQHydroxychloroquineCQChloroquineICMRIndian Council Of Medical ResearchMOHFWMinistry of Health & Family WelfarePPEPersonal Protective EquipmentPCRPolymerase Chain Reaction ER -